CVS Health Corporation $CVS Stock Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. boosted its stake in CVS Health Corporation (NYSE:CVS - Free Report) by 148.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,419,866 shares of the pharmacy operator's stock after buying an additional 2,643,571 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.35% of CVS Health worth $378,738,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of CVS Health in the second quarter valued at approximately $12,747,462,000. State Street Corp grew its holdings in CVS Health by 26.3% in the 2nd quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator's stock valued at $7,751,205,000 after buying an additional 15,604,883 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of CVS Health by 49.8% in the 2nd quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator's stock worth $3,496,725,000 after acquiring an additional 11,233,381 shares during the last quarter. Bank of America Corp DE increased its stake in shares of CVS Health by 148.0% in the 2nd quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator's stock worth $2,398,868,000 after acquiring an additional 13,836,701 shares during the last quarter. Finally, Pzena Investment Management LLC purchased a new position in shares of CVS Health during the 2nd quarter worth $1,217,558,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Improving fundamentals and valuation support the stock. CVS has recently exceeded earnings and revenue expectations, while analysts cited stronger returns, rising earnings estimates and a lower valuation than Alignment Healthcare. Its Aetna turnaround is also viewed as a potential catalyst. CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now?
• Positive Sentiment: Expanded care access and quality credentials reinforce CVS’s healthcare-services strategy. CVS opened its first pharmacy-focused location in the Boston area to improve access to medications, immunizations and other services. Separately, MinuteClinic received its seventh consecutive Joint Commission accreditation, with primary care available at more than 65% of its locations. CVS Pharmacy Celebrates Opening of First Pharmacy-Focused Location in Boston Area
• Neutral Sentiment: New women’s-health collaboration could support longer-term engagement. CVS is partnering with The Midlife Collective on a research study and documentary focused on women’s midlife health. The initiative may strengthen brand awareness and consumer relationships, but it is unlikely to have a near-term financial impact. CVS Health Collaborates With The Midlife Collective
• Positive Sentiment: Home-based heart monitoring expands value-added services. Signify Health, part of CVS, offers continuous heart-rhythm monitoring for eligible health-plan members, potentially enabling earlier detection of serious conditions and supporting preventive-care economics. CVS Health: Early Detection Matters
• Negative Sentiment: $315 million opioid settlement creates legal, financial and reputational pressure. CVS agreed to settle Justice Department allegations involving unlawful opioid dispensing and false claims. The company admitted no wrongdoing but will implement tighter controlled-substance oversight, adding costs and highlighting compliance risks. CVS Agrees to Pay $315M

CVS Health Price Performance

CVS stock opened at $92.45 on Friday. The business's 50-day moving average is $91.80 and its two-hundred day moving average is $93.03. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The firm has a market capitalization of $118.25 billion, a P/E ratio of 11.53, a P/E/G ratio of 0.84 and a beta of 0.60. CVS Health Corporation has a 1 year low of $69.51 and a 1 year high of $110.68.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping analysts' consensus estimates of $1.87 by $0.71. The business had revenue of $106.10 billion during the quarter, compared to the consensus estimate of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%. The business's revenue for the quarter was up 7.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Analysts anticipate that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd will be given a $0.6650 dividend. The ex-dividend date of this dividend is Thursday, October 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. CVS Health's dividend payout ratio is currently 70.37%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CVS. Piper Sandler set a $112.00 price target on shares of CVS Health in a research note on Wednesday, September 9th. Wells Fargo & Company increased their price objective on CVS Health from $103.00 to $123.00 and gave the stock an "overweight" rating in a research report on Monday, July 13th. Robert W. Baird set a $107.00 price objective on CVS Health in a report on Thursday, August 6th. Bank of America raised their target price on CVS Health from $100.00 to $110.00 and gave the company a "buy" rating in a report on Monday, June 22nd. Finally, BMO Capital Markets set a $112.00 target price on CVS Health in a research report on Wednesday, September 9th. Twenty equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, CVS Health presently has an average rating of "Moderate Buy" and a consensus price target of $107.80.

About CVS Health

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company's major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.